SecBot SecBot
SECBOTREPLAY Home › Report › TVTX

TVTX · Travere Therapeutics (TVTX) announced FDA approval of FILSPARI…

Travere Therapeutics, Inc. · 8-K filed Apr 13, 2026 at 20:44 ET

At the news

BULLISHIMPACT 8/10

8-K filed Apr 13, 2026 at 20:44 ET

Travere Therapeutics (TVTX) announced FDA approval of FILSPARI (sparsentan) to reduce proteinuria in adult and pediatric patients aged 8+ with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome. This marks the first and only FDA-approved treatment for FSGS, expanding FILSPARI's label beyond IgA nephropathy.

  • FDA approved FILSPARI for FSGS without nephrotic syndrome in patients aged 8 and older
  • FILSPARI is the first and only FDA-approved treatment for FSGS
  • Approval expands FILSPARI's label beyond IgA nephropathy into a second rare kidney disease
  • Phase 3 DUPLEX study showed 48% reduction in proteinuria vs 27% for irbesartan in non-nephrotic FSGS patients

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access